Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
NCT05687123
Recruiting
This phase I trial tests the safety, side effects, and best dose of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pancreatic neuroendocrine tumors. Sunitinib malate is in a class of medications called kinase inhibitors and a form of targeted therapy that blocks the action of abnormal proteins called VEGFRs that signal tumor cells to multiply. This helps stop or slow the spread of tumor cells. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +8 locations
Conditions: Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8, Stage IV Pancreatic Neuroendocrine Tumor AJCC v8, Unresectable Pancreatic Neuroendocrine Tumor
Register for Updates
Building Resilience at Schools: Emotional and Biological Assessment and Treatment of Traumatic Stress
NCT05701111
Recruiting
In the last four years alone, residents of Puerto Rico have experienced a slew of natural disasters including Hurricane Maria in 2017, earthquakes in 2019 and 2020, the continued COVID-19 pandemic from 2020-2022, and most recently Hurricane Fiona. This series of distressing events can lead to an increased need for mental health resources and trauma treatment. Furthermore, the unique single-district structure of the Puerto Rican education system allows for the efficient dissemination of potential... Read More
Gender:
ALL
Ages:
Between 11 years and 17 years
Trial Updated:
07/15/2025
Locations: Stanford University, Palo Alto, California +2 locations
Conditions: Post Traumatic Stress Disorder, Complex Posttraumatic Stress Disorder, Stress, Burn Out, Mental Health Issue
Register for Updates
Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT, a Double-blind, Randomized, Controlled Study
NCT05705999
Recruiting
This pilot study will investigate the clinical and neurophysiological effects of repetitive transcranial magnetic stimulation (rTMS) followed by comprehensive behavioral intervention for tics (CBIT) in adult patients with Tourette's Syndrome (TS). Two groups of moderate disease severity will be randomized to receive active or sham rTMS targeted to the supplementary motor area (SMA) followed by eight CBIT sessions. The change in tic frequency and severity (primary outcome) and neurophysiological... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/15/2025
Locations: WVU RNI, Morgantown, West Virginia
Conditions: Tourette Syndrome
Register for Updates
Ultrasound Guided Serratus Anterior Plane Block for Rib Fractures
NCT05748366
Recruiting
This study is a single center, randomized controlled trial examining the effect of serratus anterior plane block (SAPB) on pain, PIC scores and other clinical outcomes in emergency department patients with multiple rib fractures in comparison to the use of analgesic medication alone. Objectives 1. Compare SAPB performed in the ED setting to analgesic medication alone with regard to pain, respiratory status and PIC score of patients with multiple rib fractures. 2. Assess the safety and feasibil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Wellspan Health York Hospital, York, Pennsylvania
Conditions: Rib Fracture Multiple
Register for Updates
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer
NCT05799274
Recruiting
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: United Theranostics, Princeton, New Jersey +1 locations
Conditions: Healthy Volunteers, Pancreatic Ductal Adenocarcinoma
Register for Updates
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
NCT05827614
Recruiting
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). BBI-825 is an oral, potent, selective ribonucleotide reductase (or RNR) small molecule inhibitor. This is a first-in-human, open-label, 2-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with BBI-8... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: UCLA Medical Center, Los Angeles, California +16 locations
Conditions: Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer
Register for Updates
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
NCT05831176
Recruiting
This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage. The aim of the study is to evaluate the ef... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/15/2025
Locations: Phoenix Childrens Hospital, Phoenix, Arizona +78 locations
Conditions: Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Register for Updates
Everolimus Aging Study
NCT05835999
Recruiting
The objective of this project is to determine if mTORC1 inhibition by 24 weeks of daily (0.5 mg/day) or weekly (5 mg/week) everolimus can safely improve physiological and molecular hallmarks of aging in humans. Participants who are 55-80 years old and insulin resistant or prediabetic will be randomized to treatment and can expect to be on study for up to approximately 38 weeks. Participants aged 18-35 will not receive the intervention and can expect to be on study for up to approximately 8 weeks... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/15/2025
Locations: University of Wisconsin-Madison, Madison, Wisconsin
Conditions: Aging, Insulin Resistance
Register for Updates
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
NCT05837455
Recruiting
This study aims to utilize a novel biomarker-driven approach to guide neoadjuvant treatment selection. It is the hypothesis that this will improve clinical response for postmenopausal women with clinical stage II/III ER-positive, HER2-negative breast cancer and identify those who may not require neoadjuvant chemotherapy, with a primary focus on outcomes in Black patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Breast Cancer, Cancer of the Breast
Register for Updates
Study of Ribociclib and Everolimus in HGG and DIPG
NCT05843253
Recruiting
The goal of this study is to determine the efficacy of the study drugs ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target. The main question the study aims to answer is whether the combination of ribociclib and everolimus can prolong the life of patients diagnosed with HGG, including DIPG.
Gender:
ALL
Ages:
Between 12 months and 39 years
Trial Updated:
07/15/2025
Locations: Children's Hospital Colorado, Aurora, Colorado +17 locations
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
Register for Updates
Goal Setting to Promote Physical Activity Adherence in Midlife Adults
NCT05980052
Recruiting
Engaging in regular physical activity during midlife is a key lifestyle behavior associated with reduced risk for Alzheimer's disease and related dementias (AD/ADRD). Yet nearly half of midlife adults (48%) do not meet national physical activity guidelines. The purpose of this mechanistic trial is to identify effective goal setting techniques to enhance psychosocial processes of self-regulation for the successful promotion of PA and adherence to national PA guidelines among midlife adults, with... Read More
Gender:
ALL
Ages:
Between 45 years and 65 years
Trial Updated:
07/15/2025
Locations: Arizona State University, Phoenix, Arizona
Conditions: Physical Activity, Exercise
Register for Updates
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
NCT06013423
Recruiting
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosphamide, fludarabine and thiotepa, and TBI before a donor cord blood transplant (CBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from... Read More
Gender:
ALL
Ages:
Between 6 months and 65 years
Trial Updated:
07/15/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphatic System Neoplasm
Register for Updates